Inclusion Criteria:

          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on
             or after standard of care treatments or are ineligible or intolerant to standard of
             care for recurrent or stage IVB cervical cancer (Arms A, B and C only).

          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and must not have
             received prior systemic therapy for recurrent or stage IVB cervical cancer (Arms D and
             E only).

          -  Must have squamous, adenosquamous, or adenocarcinoma of the cervix and progressed on
             or after at least one but no more than two prior systemic therapies for recurrent or
             stage IVB cervical cancer (Arm F and G only).

          -  Must have baseline measurable disease per RECIST v1.1.

          -  Must be at least 18 years of age on the day of signing informed consent (All Arms).

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (All
             Arms).

          -  Is not pregnant, breastfeeding, or expecting to conceive children within the projected
             duration of the trial and for at least 6 months after the last trial treatment
             administration

          -  Women of childbearing potential must agree to use adequate contraception during and
             for 6 months after the last dose of trial treatment administration.

          -  Must sign an informed consent form (ICF) indicating the trial subject understands the
             purpose of and procedures required for the trial and are willing to participate in the
             trial (All Arms).

        Exclusion Criteria:

          -  Has clinically relevant bilateral hydronephrosis which cannot be alleviated by
             ureteral stents or percutaneous drainage. (All Arms)

          -  Has clinical signs or symptoms of gastrointestinal obstruction and requires parenteral
             hydration and/or nutrition. Post-operative obstructions within 4 weeks of abdominal
             surgery are permitted. (All Arms)

          -  Has clinically significant bleeding issues or risks

          -  Prior history (within 3 months) or current evidence of hemoptysis (1/2 teaspoon or
             more) (Arm A only)

          -  Recent (within 4 weeks of first dose of trial treatment) clinically significant
             gastrointestinal or vaginal bleeding requiring PRBC transfusion (Arm A only)

          -  Recent (within 4 weeks of first dose of trial treatment) evidence of wound healing
             complications that require medical intervention (Arm A only)

          -  Has active ocular surface disease at baseline. Subjects with prior history of
             cicatricial conjunctivitis are ineligible (All Arms).

          -  Clinically significant cardiac disease

          -  Requires anti-coagulation therapy